The estimated Net Worth of & Johnson Johnson & Johnson... is at least $212 million dollars as of 30 June 2020. Johnson owns over 725,000 units of Fusion Pharmaceuticals stock worth over $79,099,620 and over the last 20 years sold FUSN stock worth over $133,278,054.
Sign up
Johnson FUSN stock SEC Form 4 insiders trading
has made over 16 trades of the Fusion Pharmaceuticals stock since 2004, according to the Form 4 filled with the SEC. Most recently bought 725,000 units of FUSN stock worth $12,325,000 on 30 June 2020.
The largest trade 's ever made was selling 18,367,346 units of Fusion Pharmaceuticals stock on 20 November 2017 worth over $50,510,202. On average, trades about 1,155,708 units every 294 days since 2004. As of 30 June 2020 still owns at least 3,670,516 units of Fusion Pharmaceuticals stock.
You can see the complete history of Johnson stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
What's Johnson's mailing address?
's mailing address filed with the SEC is ONE JOHNSON & JOHNSON PLAZA410 GEORGE STREET, , NEW BRUNSWICKNEW BRUNSWICK, NJNJ, 0893308901.
Insiders trading at Fusion Pharmaceuticals
Over the last 4 years, insiders at Fusion Pharmaceuticals have traded over $1,703,181 worth of Fusion Pharmaceuticals stock and bought 2,415,900 units worth $40,298,362 . The most active insiders traders include Group Holdings (Sbs) Adviso..., Street Partners Llc Adams et & Johnson Johnson & Johnson.... On average, Fusion Pharmaceuticals executives and independent directors trade stock every 28 days with the average trade being worth of $2,030,355. The most recent stock trade was executed by Steven Gannon on 11 August 2022, trading 44,400 units of FUSN stock currently worth $90,132.
What does Fusion Pharmaceuticals do?
Fusion Pharmaceuticals Inc., a clinical-stage oncology company, focuses on developing radiopharmaceuticals as precision medicines. The company has developed Targeted Alpha Therapies platform together with its proprietary Fast-Clear linker technology to enable us to connect alpha particle emitting isotopes to antibodies and other targeting molecules in order to selectively deliver the alpha particle payloads to tumors. Its lead product candidate is FPI-1434 that is in Phase 1 clinical trials as a monotherapy in patients with solid tumors expressing insulin-like growth factor 1 receptor. The company is also conducting additional preclinical studies of FPI-1434 in combination with approved checkpoint inhibitors and DNA damage response inhibitors to further assess the anti-tumor activity, and dosing schedule and pharmacodynamics of the combinations. In addition, it is progressing its earlier-stage product candidate, FPI-1966 into clinical development for the treatment of head and neck, and bladder cancers expressing fibroblast growth factor receptor. The company was founded in 2014 and is headquartered in Hamilton, Canada.
What does Fusion Pharmaceuticals's logo look like?
Complete history of Johnson stock trades at Aldeyra Therapeutics Inc, Genocea Biosciences Inc, Minerva Neurosciences Inc, Protagonist Therapeutics Inc, Nevro Corp, Inspire Medical Systems Inc, Cortexyme Inc et Fusion Pharmaceuticals
Fusion Pharmaceuticals executives and stock owners
Fusion Pharmaceuticals executives and other stock owners filed with the SEC include:
-
Dr. John F. Valliant,
Founder, CEO & Director -
John J. Crowley CPA,
Chief Financial Officer -
Dr. Eric Burak Ph.D.,
Chief Technology Officer -
Dr. James J. O'Leary,
Chief Medical Officer -
Dr. Eric Burak,
Chief Scientific Officer -
Eric S. Hoffman Ph.D.,
Sr. VP of Bus. Devel. -
Dr. Isabelle Dussault Ph.D.,
Sr. VP of Research -
Dr. Christopher Paul Leamon Ph.D.,
Chief Scientific Officer -
Mohit Rawat,
Pres & Chief Bus. Officer -
Dr. Marc Schwabish,
SVP of Bus. Devel. and US Operations -
Maria D. Stahl,
Chief Legal Officer -
Amanda Cray,
Sr. Director of Investor Relations & Corp. Communications -
Lynn Wick,
Exec. Director of Fin. & Operations -
Group Holdings (Sbs) Adviso...,
-
Johan Christenson,
Director -
Vii, L.P.Health Cap Vii Gp ...,
-
Heather Preston,
Director -
Street Partners Llc Adams,
10% owner -
James J O'leary,
Chief Medical Officer -
Chau Quang Khuong,
Director -
Advisors Llc Orbi Med Capit...,
-
& Johnson Johnson & Johnson...,
-
Steven Gannon,
-
Teresa Marie Bitetti,
-
Jeremy Bender,
-
Pablo J Cagnoni,
-
Donald A Bergstrom,
-
Christopher P Leamon,
Chief Scientific Officer -
Mohit Rawat,
President & CBO -
David D. Meek,
-
Dmitri Bobilev,
Chief Medical Officer -
Eric Burak,
Chief Technology Officer -
John J Crowley,
Chief Financial Officer -
John Valliant,
Chief Executive Officer -
Philina Lee,
-
Barbara Gayle Duncan,